A0A8C9HY57 (A0A8C9HY57_9PRIM) Piliocolobus tephrosceles (Ugandan red Colobus)
Histone deacetylase UniProtKBInterProInteractive Modelling
488 aa; Sequence (Fasta) ;
4 identical sequences: Homo sapiens: Q92769; Pan troglodytes: K7B9A4, A0A803KJY1; Gorilla gorilla gorilla: G3QRQ8
It is possible new templates exist for this target since these models were created.
Available Structures
39 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
Cryo-EM structure of the human SIN3B histone deacetylase core complex with SAHA at 2.8 Angstrom |
Heteromer O75182; Q92769; Q96QT6; | 1×SHH; 3×ZN; 2×CA; | ||||
Assess | ||||||
Cryo-EM structure of the human SIN3B histone deacetylase complex at 3.7 Angstrom |
Heteromer O75182; Q92769; Q96QT6; Q9UBU8; | 5×ZN; 2×CA; | ||||
Assess | ||||||
Cryo-EM structure of the human SIN3B full-length complex at 3.4 Angstrom resolution |
Heteromer O75182; Q92769; Q96QT6; Q9UBU8; | 5×ZN; 2×CA; | ||||
Assess | ||||||
Cryo-EM structure of the human SIN3B histone deacetylase core complex at 2.8 Angstrom |
Heteromer O75182; Q92769; Q96QT6; | 3×ZN; 2×CA; 1×ACT; | ||||
Assess | ||||||
Histone deacetylases complex with peptide macrocycles | monomer | 1×ZN; 2×NA; 1×NHE; 3×PG4; 1×PGE; 1×PEG; | ||||
Assess | ||||||
Histone deacetylases complex with peptide macrocycles | monomer | 1×ZN; 2×NA; 2×NHE; 2×PG4; 1×PGE; | ||||
Assess | ||||||
Histone deacetylases complex with peptide macrocycles | monomer | 1×ZN; 2×NA; 1×NHE; 2×PGE; 1×PG4; | ||||
Assess | ||||||
Histone deacetylases complex with peptide macrocycles | monomer | 1×ZN; 2×NA; 1×NHE; 1×PGE; 2×PG4; | ||||
Assess | ||||||
Histone deacetylases complex with peptide macrocycles | monomer | 1×ZN; 2×NA; 2×PGE; | ||||
Assess | ||||||
Structure of HDAC2 complexed with an inhibitory ligand | monomer | 1×ZN; 1×CA; 1×NA; 1×PGE; 6×EDO; 1×KJ6; 1×2OP; | ||||
Assess | ||||||
Ligand binding to HDAC2 | monomer | 1×ZN; 1×CA; 1×NA; 2×PEG; 1×PGE; 1×KJF; | ||||
Assess | ||||||
HDAC2 WITH LIGAND BRD7232 | monomer | 1×ZN; 2×CA; 1×6EZ; 2×PEG; 1×PG4; 1×PG5; 2×PGE; | ||||
Assess | ||||||
Inhibitor binding to HDAC2 | monomer | 1×ZN; 1×CA; 1×NA; 1×PEG; 1×KRU; | ||||
Assess | ||||||
HDAC2 complexed with an inhibitory ligand | monomer | 1×ZN; 1×CA; 1×NA; 3×PEG; 1×EDO; 1×SHH; 1×KK0; | ||||
Assess | ||||||
HDAC2 in complex with inhibitory ligand | monomer | 1×ZN; 1×CA; 1×NA; 4×EDO; 1×KJN; | ||||
Assess | ||||||
Crystal structure of human HDAC2 in complex with (R)-6-[3,4-Dioxo-2-(4-trifluoromethoxy-phenylamino… | monomer | 1×ZN; 1×CA; 1×NA; 1×EL8; | ||||
Assess | ||||||
Structure of Human HDAC2 in complex with a 2-substituted benzamide inhibitor (compound 20) | monomer | 1×ZN; 2×CA; 4×SO4; 3×PEG; 1×WBA; | ||||
Assess | ||||||
Structure of Human HDAC2 in complex with an ethyl ketone inhibitor containing a spiro-bicyclic group | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×TV7; | ||||
Assess | ||||||
STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND E) | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×V1P; | ||||
Assess | ||||||
Structure of HDAC2 in complex with an inhibitor (compound 9) | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×V1P; | ||||
Assess | ||||||
Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 25) | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×ZL4; | ||||
Assess | ||||||
STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ARYL KETONE INHIBITOR | monomer | 1×ZN; 2×CA; 4×SO4; 3×PEG; 1×V1D; | ||||
Assess | ||||||
Structure of Human HDAC2 in complex with inhibitor 4-(acetylamino)-N-[2-amino-5-(thiophen-2-yl)phen… | monomer | 1×ZN; 1×CA; 1×NA; 3×PG4; 1×20Y; | ||||
Assess | ||||||
STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ETHYL KETONE INHIBITOR CONTAINING A SPIRO-BICYCLIC GROU… | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×VJV; | ||||
Assess | ||||||
HDAC2 WITH LIGAND BRD4884 | monomer | 1×ZN; 2×CA; 1×IWX; 1×PG5; 2×PGE; | ||||
Assess | ||||||
Structure of HDAC2 in complex with an inhibitor (compound 14) | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×ZLS; | ||||
Assess | ||||||
STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND O) | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×V1S; | ||||
Assess | ||||||
Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 4) | monomer | 1×ZN; 5×SO4; 2×CA; 3×PEG; 1×ZLV; | ||||
Assess | ||||||
Structure of HDAC2 in complex with an inhibitor (compound 19) | monomer | 1×ZN; 4×SO4; 2×CA; 3×PEG; 1×ZLM; | ||||
Assess | ||||||
Structure of Human HDAC2 in complex with SAHA (vorinostat) | monomer | 1×ZN; 1×CA; 1×NA; 3×PG4; 1×SHH; | ||||
Assess | ||||||
HDAC2 in complex with an inhibitor | monomer | 1×ZN; 1×CA; 1×NA; 1×KIZ; | ||||
Assess | ||||||
Structure of Human HDAC2 in complex with a 2-substituted benzamide inhibitor (compound 16) | monomer | 1×ZN; 2×CA; 3×PEG; 1×WB4; | ||||
Assess | ||||||
Structure of Human HDAC2 in complex with an ethyl ketone inhibitor | monomer | 1×TV1; 1×ZN; 2×CA; 3×PEG; | ||||
Assess | ||||||
STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR LACKING A ZINC BINDING GROUP (COMPOUND 19) | monomer | 1×ZN; 4×SO4; 2×CA; 1×ACT; 3×PEG; 1×YEV; | ||||
Assess | ||||||
STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR THAT LACKS A ZINC BINDING GROUP (COMPOUND 12) | monomer | 1×ZN; 2×CA; 1×ACT; 3×PEG; 1×YEM; | ||||
Assess | ||||||
Ligand binding to HDAC2 | monomer | 3×PEG; 1×PG4; 1×EDO; 1×ZN; 1×CA; 1×NA; 1×KKW; 1×KZF; | ||||
Assess | ||||||
STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH APICIDIN | monomer | 1×ZN; 2×CA; 3×PEG; 1×YED; | ||||
Assess | ||||||
Inhibitory Ligand binding to HDAC2 | monomer | 5×EDO; 1×PG4; 3×PEG; 1×ZN; 1×CA; 1×NA; 1×KKI; 1×NHE; | ||||
Assess | ||||||
Crystal Structure of Human HDAC2 complexed with an N-(2-aminophenyl)benzamide | monomer | 1×ZN; 1×CA; 1×NA; 1×LLX; 1×NHE; | ||||
Assess |
1 SWISS-MODEL model
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
7zzo.1.A | monomer | 0.89 | 1×ZN; 1×CA; 1×KIZ; | 100.00 | ||
Assess |